awmsg logo



collagenase Clostridium histolyticum (Xiapex®)


Reference No. 930

Publication date:
12/01/2012


Appraisal information

collagenase Clostridium histolyticum (Xiapex®) 0.9 mg powder and solvent for solution for injection


Company: Swedish Orphan Biovitrum Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 05/10/2011
AWMSG meeting date: 09/11/2011
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1711
Ministerial ratification: 20/12/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Collagenase Clostridium histolyticum (Xiapex®) is recommended as an option for restricted use within NHS Wales for the treatment of Dupuytren’s contracture in adult patients with a palpable cord. Collagenase Clostridium histolyticum (Xiapex®) should be restricted for use as an alternative to fasciectomy in a subset of adult patients with a total of two or less affected joints per hand where percutaneous needle fasciotomy is not appropriate, using up to three injections per cord, with no more than six injections per patient. AWMSG is of the opinion that collagenase Clostridium histolyticum (Xiapex®) is not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download